AMG330, a human bispecific T-cell engager (BiTE) against CD33/CD3, produced a potent T-cell cytotoxic response against primary AML [327] and was tested in a phase I trial (NCT02520427). The gene discussed is CD33; the disease is acute myeloid leukemia.